News Digest / Ticker: PPCB

Ticker: PPCB

08:16am, Monday, Aug 25, 2025

Propanc (PPCB) nets $4M in Nasdaq debut; 45-day 150K option and PRP Phase 1B CTA set for H1 2026

Propanc Biopharma (NASDAQ: PPCB) quietly raised $4M in August. Lead PRP IV therapy targets a Phase 1B CTA in H1 2026 (30-40 pts); Rec‑PRP pharmacology due Q1 2026. Small raise fuels headline-driven volatility and dilution risk.

04:04pm, Thursday, May 15, 2025

Propanc Biopharma Reports $54.9M Loss Amid Rising Expenses, Faces Financial Struggles Ahead